EMEA makes safety recommendations for Ritalin use
This article was originally published in Scrip
The EMEA has made recommendations for safer use of Novartis's Ritalin (methylphenidate) and other methylphenidate-containing medications following concerns over possible cardiovascular and cerebrovascular risks, and psychiatric disorders in children and adolescents.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.